Insights on Immunotherapy in Daily Clinical Practice - priME Oncology
Webcast
Webcast

Insights on Immunotherapy in Daily Clinical Practice

Clinical Application and Emerging Opportunities

Not a member of My prIME? Join now for instant access.

Hear from the experts’ case-based, multidisciplinary discussions focusing on lung cancer, head & neck cancer, and urologic malignancies. Treatment plans, specific clinical-pathologic criteria, and headline data will be discussed to support the proposed treatment option. Furthermore, emerging data in other disease areas for which immunotherapy is not yet fully established will be presented.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

XX AMA PRA Category 1 Credits

Release Date

Release Date

Nov 16, 2018

Expiration Date

Nov 16, 2019

Introduction
Patient selection for immunotherapy: Making sense of current and emerging biomarkers
Mario Colombo, PhD

Coping With the Whirlwind of Change in Lung Cancer Treatment: A Multidisciplinary Team Discussion
Clinical scenario 1: First-line therapy for metastatic lung cancer
David Planchard, MD, PhD

Clinical scenario 2: Locally advanced lung cancer
David Planchard, MD, PhD

The Emerging Role for Immunotherapy in Head & Neck Cancer: A Multidisciplinary Team Discussion
Clinical scenario 1: Platinum-resistant advanced head & neck cancer
Jean-Pascal Machiels, MD, PhD

The Expanding Role of Immunotherapy for Urologic Malignancies: A Multidisciplinary Team Discussion
Clinical scenario 1: First-line therapy for metastatic bladder cancer
David I. Quinn, MBBS, PhD, FRACP, FACP

Clinical scenario 2: Second-line therapy for metastatic bladder cancer
David I. Quinn, MBBS, PhD, FRACP, FACP

Clinical scenario 3: A patient with BRCA-positive, endocrine-resistant metastatic prostate cancer
David I. Quinn, MBBS, PhD, FRACP, FACP

Extending immunotherapy beyond established indications
Giuseppe Curigliano, MD, PhD

Conclusions and prIME Points™
Giuseppe Curigliano, MD, PhD

  • Mario Colombo, PhDFondazione IRCCS - Istituto Nazionale dei Tumori
    Milan, Italy
  • Giuseppe Curigliano, MD, PhDEuropean Institute of Oncology
    University of Milan
    Milan, Italy
  • Jean-Pascal Machiels, MD, PhDCliniques universitaires Saint-Luc
    Université catholique de Louvain
    Brussels, Belgium
  • David Planchard, MD, PhDGustave Roussy
    Villejuif, France
  • David I. Quinn, MBBS, PhD, FRACP, FACPUniversity of Southern California
    Norris Cancer Hospital
    Los Angeles, California, United States

This educational activity is intended for medical oncologists and other healthcare professionals interested in immunotherapy approaches for solid tumors.

After successful completion of this educational activity, participants should be able to:

  • Describe the clinical application of checkpoint inhibitors to the treatment pathways for lung, bladder, and head & neck cancer
  • Discuss the current and emerging data with checkpoint inhibition in prostate, breast, ovarian, and colorectal cancer
  • Apply the use of biomarkers to guide treatment selection
  • Incorporate multidisciplinary strategies to monitor and manage immune-related adverse events

Perspectives on Immunotherapy in Daily Clinical Practice

Listen to our experts providing a brief summary on key data supporting the use of immunotherapy in lung cancer, head & neck cancer, and urologic malignancies, as well as the use of immunotherapy beyond current established indications.

This educational activity is supported by a grant from AstraZeneca Pharmaceuticals LP.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this online activity for a maximum of XX AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Colombo has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Curigliano has disclosed that he has received consulting fees and honoraria for promotional speakers’ bureaus from Pfizer and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Machiels has disclosed that he is a member on the advisory board of Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Debiopharm Group, Innate Pharma, Merck Serono, and Merck Sharp & Dohme Corp. He is also a speaker and teacher for Merck Sharp & Dohme Corp and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Planchard has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme Corp, Novartis, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Quinn has disclosed that he has received board membership fees and consulting fees from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Dendreon, EMD Serono, Exelixis, Genentech/Roche, Janssen, Merck Sharp & Dohme Corp, Novartis, Pfizer, and Sanofi. He is also independently contracted by Genentech, GlaxoSmithKline, Millennium, and Sanofi. He has disclosed membership on advisory committee or review panel for Eisai. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.